$ News

OneSpaWorld Holdings Will Replace Dynavax Technologies In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On February 10,2026

Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED)

Nvidia, Sobr Safe And 3 Stocks To Watch Heading Into Friday

Dynavax Technologies (DVAX) Shares Are Trending Overnight — Here's Why

Nike, Omeros Corporation, Micron Technology, Intel And Dynavax Technologies: Why These 5 Stocks Are On Investors' Radars Today

William Blair Downgrades Dynavax Technologies to Market Perform

Dynavax Technologies shares are trading higher after Sanofi announced it will acquire the company.

Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy

Sanofi Agrees To Buy Dynavax At $15.50 Per Share Valuing Company At $2.2B And Representing 39% Premium, Expanding Presence In Adult Immunization And Vaccine Development

Why Dynavax Technologies (DVAX) Is Up 5.7% After Launching a $100 Million Buyback and Raising Guidance

Dynavax Technologies Corp (DVAX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Dynavax Technologies Corporation (DVAX) Q3 2025 Earnings Call Transcript

Dynavax Technologies Corporation 2025 Q3 - Results - Earnings Call Presentation

Dynavax Technologies: Q3 Earnings Snapshot

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

Dynavax Is Providing FY25 Financial Guidance, Based On Its Current Operating Plan; HEPLISAV-B Net Product Revenue Is Expected In The Range Of $315M-$325M; Adjusted EBITDA Is Expected To Be At Least $80M, An Increase Compared To The Prior Guidance Of At Least $75M

Dynavax Technologies Collaborates With Vaxart To Develop, Commercialize COVID-19 Vaccines On Vaxart's Platform; Dynavax Will Pay $25M Upfront License Fee, $5M Equity Investment In Vaxart

Dynavax Announces New $100M Share Repurchase Program

Dynavax Technologies Q3 EPS $0.21 Beats $0.12 Estimate, Sales $94.876M Beat $94.003M Estimate